GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
By Lori Solomon HealthDay Reporter
FRIDAY, July 26, 2024 -- In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of DR progression compared with sodium-glucose cotransporter 2 inhibitors (SGLT2is), according to a study published online July 19 in Diabetes, Obesity and Metabolism.
Donna Shu-Han Lin, M.D., from Shin Kong Wu Ho-Su Memorial Hospital in Taipei, Taiwan, and colleagues examined the effects of GLP1RAs and SGLT2is on the development or progression of DR. Analysis included 1,517 patients treated with a GLP1RA with DR and 9,549 without DR and 3,034 patients treated with an SGLT2i with DR and 19,098 without DR.
The researchers found that in patients with preexisting DR, the incidence of any DR progression event was significantly higher in the GLP1RA group than the SGLT2i group (subdistribution hazard ratio, 1.50). This risk of progression was driven by increased risk of tractional RD. In patients without DR at baseline, the groups had similar risk for all ocular outcomes.
"The hazards of retinal events associated with GLP1RA use are probably accentuated in those with a higher baseline risk; whether this is related to more rapid glycemic control with GLP1RA use remains to be elucidated," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.